Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 11, Issue 9, Pages 2631
Publisher
MDPI AG
Online
2022-05-08
DOI
10.3390/jcm11092631
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
- (2022) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Treatment of Nail Psoriasis
- (2022) Martin Kassir et al. Journal of Drugs in Dermatology
- Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
- (2022) Giacomo Caldarola et al. Dermatologic Therapy
- Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis
- (2021) I-Hsin Huang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five‐year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)
- (2021) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management
- (2021) Julie J. Hong et al. Dermatology and Therapy
- Successful management of treatment resistant nail psoriasis with tildrakizumab
- (2021) Kate Simpson et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients
- (2021) Katharina A. Drerup et al. DERMATOLOGY
- Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations
- (2021) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tildrakizumab: short‐term efficacy and safety in real clinical practice
- (2021) Manuel Galán‐Gutierrez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment
- (2020) Fathima F. Ismail et al. Dermatologic Therapy
- Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma
- (2020) Caterina Lanna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
- (2020) MA Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
- (2020) Norman Wasel et al. Dermatology and Therapy
- Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study
- (2020) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience
- (2020) Claudio Bonifati et al. Dermatologic Therapy
- Successful treatment of psoriatic crumbly nails with ustekinumab
- (2019) Marco Galluzzo et al. Dermatologic Therapy
- Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
- (2019) Boni Elewski et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis
- (2018) C. Ryan et al. BRITISH JOURNAL OF DERMATOLOGY
- Prevalence of genital psoriasis in patients with psoriasis
- (2018) Kim A. P. Meeuwis et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
- (2018) Boni E. Elewski et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
- (2018) Peter Foley et al. JAMA Dermatology
- “GENIPSO”: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis
- (2018) M. Larsabal et al. BRITISH JOURNAL OF DERMATOLOGY
- Topology of Psoriasis in Routine Care - Results from a High-resolution Analysis in 2,009 Patients
- (2018) M. Augustin et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment Approaches to Moderate to Severe Psoriasis
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis
- (2017) P. Gisondi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects
- (2016) Inês Raposo et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Prevalence of psoriasis phenotypes among men and women in the USA
- (2016) J. F. Merola et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
- (2015) R.G. Langley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study
- (2014) D. Thaçi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Psoriatic arthritis and nail changes: Exploring the relationship
- (2014) Matthew K. Sandre et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling
- (2013) Lin Xie et al. Patient Preference and Adherence
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails
- (2011) Zoe R Ash et al. ANNALS OF THE RHEUMATIC DISEASES
- Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
- (2011) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Scalp psoriasis
- (2010) Gottfried Wozel et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation
- (2009) C. Stanley Chan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease
- (2009) D McGonagle JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials
- (2008) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More